profit from every $100 of sales.
$0$100
Exicure
$1.08+1.89% today
-70.4% in 1 year
1-year low $0.891-year high $7.29
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Exicure sold, what it kept, and what it did with the cash.
Sales went from $28.8 million in 2022 to $0 in 2025, with -$4.95 million of profit last year.
SalesProfit
Exicure vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Exicure | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Exicure's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29 | 0 | 1 | 0 | |
| – | – | – | – | |
| -2 | -13 | -5 | -10 | |
| 0 | -16 | -9 | -5 | |
| -3 | -17 | -10 | -5 | |
| -2.80 | -10.55 | -4.75 | -0.79 | |
| – | – | – | – | |
| -6.4% | – | -989.8% | – | |
| -9.0% | – | -1,940.2% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23 | 12 | 15 | 14 |
| Cash | 9 | 1 | 13 | 4 |
| Total debt | 7 | 7 | 6 | 0 |
| Total liabilities | 8 | 9 | 8 | 10 |
| 15 | 3 | 7 | 4 | |
| 1 | 2 | 2 | 6 | |
| -6.3% | -137.8% | -60.1% | -107.4% | |
| -17.3% | -558.0% | -143.3% | -126.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -36 | -10 | -3 | -9 | |
| 0 | – | – | 0 | |
| -36 | -10 | -3 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 9.1×
- 14.1×
- –
- –
- -41.2%
- -137.2%
- 0.0%
Profitability
- 0.0%
- -989.8%
- -1,940.2%
- 0.0%
- -99.6%
- -126.0%
- -179.4%
- -76.7%
- -106.0%
- –
Growth
- −86.8%
- –
- −194.0%
- –
- +20.8%
Financial health
- -0.7×
- 0.00
- 0.0%
- -8,796.0×
- 0.79
- 0.79
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 946
Bottom 1%of 868
Bottom 1%of 986
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 25, 2026 | -0.46 | -18.60 | +97.5% |
| Nov 7, 2025 | -0.39 | – | – |
| Aug 8, 2025 | -0.41 | – | – |
| Jun 27, 2025 | -0.45 | – | – |
| Mar 18, 2025 | -3.39 | – | – |
| Nov 14, 2024 | -0.57 | – | – |
| Aug 13, 2024 | -0.35 | – | – |
| Jun 17, 2024 | -0.50 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
24No pass
Philip Fisher
35No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
29No pass
Questions about Exicure
Is Exicure a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Exicure AI analysis
What does Exicure do?
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. It is in Biotechnology.
Does Exicure pay a dividend?
No. Exicure does not pay a dividend at the moment.
Is Exicure stock halal?
No. Exicure does not pass our halal screen: its cash and confirmed interest-bearing investments are 53% of its market value, at or above the 33% limit. How we check
How has Exicure stock done over the past year?
Down 70.4% over the past twelve months, to $1.08. It traded between $0.89 and $7.29 and is 85.2% below its high.
Who are Exicure's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Exicure's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.